Almac Group Receives Grant for COVID-19 Clinical Study
The company has received a $288,000 grant from the COVID-19 Therapeutics Accelerator, part of the Bill & Melinda Gates Foundation, to support a clinical study in Sub-Saharan Africa to find a treatment for COVID-19.
Almac Group, a contract development and manufacturing organization, announced on May 28, 2020 that it has received a $288,000 grant from the COVID-19 Therapeutics Accelerator, part of the Bill & Melinda Gates Foundation, to support a clinical study in Sub-Saharan Africa to find a treatment for COVID-19.
According to a company press release, Almac Clinical Services will offer clinical trial solutions from protocol through to patient delivery and will ship all supplies to the clinical site, while Almac Sciences will provide analytical support from the company’s Craigavon, Northern Ireland headquarters. Additionally, the company will support a second, open-label clinical study through the distribution of commercial packs to a pharmacy in South Africa.
“This virus is threatening peoples’ lives and livelihoods and nowhere worse than in the poorer regions of the world,” said Dr. Robert Dunlop, managing director and president, Almac Clinical Services, in the press release. “Almac’s global capabilities and expertise enable us to play our part and support efforts to find a vaccine and/or treatment for coronavirus. We are delighted to be awarded this grant from the COVID-19 Therapeutics Accelerator and to be supporting these clinical studies in Sub-Saharan Africa.”
Source: Almac
